Crispr Therapeutics Ag (CRSP) Stock Price, Quote & News

Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 41 561 32 77

Website: www.crisprtx.com

Address:

Baarerstrasse 14, Zug, Switzerland

burbs88 Aug. 6 at 6:44 PM

$CRSP I think we've established a 50 dollar floor here. Based on this price action, shorts should be learning they're not going to be able to slow bleed it, like every previous spike. They SHOULD be learning that...but, they probably won't and just get themselves stuck, injured in the middle of the road and runnover by a tractor trailer.

0 · Reply

Surf_City_USA Aug. 6 at 6:35 PM

$CRSP Holding mine for the big celebration day. 😉

1 · Reply

RT69 Aug. 6 at 5:16 PM

$CRSP I won’t be happy, until this reaches $120+! Thinking this can reach $250-500 within 3 years. What do you all think?

1 · Reply

Coconutbeater Aug. 6 at 4:29 PM

$CRSP partnership with Sirius was an incredible situation as well. First it adds a best in class treatment under their control, plus an additional 2 therapy options to be exclusively under CRSP control in the future if they choose. Obviously it was at a cost of almost 100 million, but it they have the cash and they have the treatment centers now to build out all future treatment. Lets roll!!!

0 · Reply

p44851 Aug. 6 at 4:16 PM

$CRSP well you were right on the move higher. I just hope you’re right on the over 60

0 · Reply

Coconutbeater Aug. 6 at 4:10 PM

$CRSP My biggest concern was the scaling of the treatment centers plus the insurance company payer situation. Vertex has done an incredible job setting this up. Crsp partnering with Vertex was a great decision.

0 · Reply

boston_drew Aug. 6 at 3:58 PM

$CRSP We will be over 60+ today - it's the typical hard drop on arguably confusing Q2 numbers but the trend to 70+ is written into this stock no matter what the quarter says ---- long term investing going on ---

0 · Reply

gargoyl Aug. 6 at 3:31 PM

$CRSP 👇 👀 peeps

0 · Reply

JarvisFlow Aug. 6 at 2:13 PM

Barclays has adjusted their stance on CRISPR Therapeutics ( $CRSP ), setting the rating to Equal-Weight with a target price of 42 → 56.

0 · Reply

p44851 Aug. 6 at 12:49 PM

$CRSP what did VRTX say that was positive

2 · Reply

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 11:03 AM EDT - 14 days ago

Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big

Jul 15, 2025, 12:01 PM EDT - 22 days ago

The Big 3: ASML, GOOGL, CRSP

ASML GOOG GOOGL

Jul 14, 2025, 8:00 AM EDT - 23 days ago

Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade)

Jun 26, 2025, 7:00 AM EDT - 5 weeks ago

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

Jun 23, 2025, 12:01 PM EDT - 6 weeks ago

The Big 3: CRSP, OKLO, GME

OKLO GME

Jun 13, 2025, 6:27 PM EDT - 7 weeks ago

Crispr Therapeutics: Betting On A One-Shot Future

Jun 9, 2025, 5:50 PM EDT - 2 months ago

CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Jun 3, 2025, 4:07 PM EDT - 2 months ago

CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)

May 29, 2025, 8:30 AM EDT - 2 months ago

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

May 9, 2025, 7:14 AM EDT - 3 months ago

Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines

May 8, 2025, 8:36 AM EDT - 3 months ago

CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)

May 7, 2025, 4:03 PM EDT - 3 months ago

Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course

May 7, 2025, 2:17 PM EDT - 3 months ago

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

May 7, 2025, 8:39 AM EDT - 3 months ago

These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

May 6, 2025, 4:01 PM EDT - 3 months ago

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

May 5, 2025, 4:44 AM EDT - 3 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

NTLA

Apr 8, 2025, 3:29 PM EDT - 4 months ago

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)

Apr 3, 2025, 8:00 AM EDT - 4 months ago

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 4:01 PM EDT - 4 months ago

CRISPR Therapeutics Announces Transition of Chief Operating Officer

Mar 25, 2025, 11:03 AM EDT - 4 months ago

CRISPR Therapeutics Set To Reach Previous Heights

Mar 3, 2025, 3:28 PM EST - 5 months ago

CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)

Feb 26, 2025, 8:00 AM EST - 5 months ago

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 13, 2025, 11:06 AM EST - 6 months ago

Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future

Feb 11, 2025, 4:01 PM EST - 6 months ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 5, 2025, 4:16 PM EST - 6 months ago

CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)

Feb 5, 2025, 3:48 PM EST - 6 months ago

Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)

Jan 15, 2025, 7:20 PM EST - 7 months ago

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers

Jan 14, 2025, 7:39 PM EST - 7 months ago

CRISPR Therapeutics AG (CRSP) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Jan 8, 2025, 8:30 AM EST - 7 months ago

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 29, 2024, 12:56 PM EST - 7 months ago

Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025

Dec 9, 2024, 12:00 PM EST - 8 months ago

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

Nov 20, 2024, 9:28 PM EST - 9 months ago

CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)

Nov 15, 2024, 11:37 AM EST - 9 months ago

CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)

Nov 14, 2024, 8:30 AM EST - 9 months ago

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 11, 2024, 12:54 PM EST - 9 months ago

Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism

Nov 5, 2024, 9:01 AM EST - 9 months ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Oct 28, 2024, 6:36 AM EDT - 10 months ago

Crispr Therapeutics: Poised For A Major Turnaround

Oct 6, 2024, 2:00 PM EDT - 10 months ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY EDIT EXAS NTLA

Sep 18, 2024, 9:11 AM EDT - 11 months ago

Crispr Therapeutics: Prepare To Be Bored

Aug 14, 2024, 6:08 AM EDT - 1 year ago

Crispr's Casgevy Launch: Promising Start, Uncertain Future

Aug 7, 2024, 10:41 AM EDT - 1 year ago

Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential

Aug 5, 2024, 4:01 PM EDT - 1 year ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Jul 7, 2024, 8:30 AM EDT - 1 year ago

Crispr Therapeutics: Beaten Down But Not Broken

Jun 11, 2024, 12:32 PM EDT - 1 year ago

CRISPR Therapeutics (CRSP) Presents at Goldman Sachs 45th Annual Global Healthcare Conference - Company Call Transcript

Jun 10, 2024, 10:27 AM EDT - 1 year ago

Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)

Jun 7, 2024, 6:26 PM EDT - 1 year ago

The 'Undercovered' Dozen From June 1-6

ALNY CLOV ENVX GAM HAL LPA PEO

Jun 6, 2024, 12:40 AM EDT - 1 year ago

CRISPR Therapeutics AG (CRSP) Jefferies 2024 Global Healthcare Conference (Transcript)

May 24, 2024, 7:40 PM EDT - 1 year ago

Final Trade: UAL, NKE, SLV & CRSP

SLV NKE UAL

May 23, 2024, 8:00 AM EDT - 1 year ago

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

burbs88 Aug. 6 at 6:44 PM

0 · Reply

Surf_City_USA Aug. 6 at 6:35 PM

$CRSP Holding mine for the big celebration day. 😉

1 · Reply

RT69 Aug. 6 at 5:16 PM

$CRSP I won’t be happy, until this reaches $120+! Thinking this can reach $250-500 within 3 years. What do you all think?

1 · Reply

Coconutbeater Aug. 6 at 4:29 PM

0 · Reply

p44851 Aug. 6 at 4:16 PM

$CRSP well you were right on the move higher. I just hope you’re right on the over 60

0 · Reply

Coconutbeater Aug. 6 at 4:10 PM

0 · Reply

boston_drew Aug. 6 at 3:58 PM

0 · Reply

gargoyl Aug. 6 at 3:31 PM

$CRSP 👇 👀 peeps

0 · Reply

JarvisFlow Aug. 6 at 2:13 PM

Barclays has adjusted their stance on CRISPR Therapeutics ( $CRSP ), setting the rating to Equal-Weight with a target price of 42 → 56.

0 · Reply

p44851 Aug. 6 at 12:49 PM

$CRSP what did VRTX say that was positive

2 · Reply

boston_drew Aug. 6 at 11:59 AM

$CRSP we ahould move much higher in near term the report and Vertex comments will slowly be understood as positive and people realize next results will be higher

0 · Reply

Bishop2D2 Aug. 6 at 3:05 AM

$CRSP This one needs to find a cure for its own bi-polarism...

1 · Reply

Coconutbeater Aug. 6 at 1:10 AM

$CRSP has not revealed the updates on pipeline. Did traders sell before finding that out? yes. are all the treatment centers up and running? yes. there is a reason that all the sales were gobbled up under $55. For a company that is establishing a completely new treatment for an incurable disease, I think everything so far is going to plan. remember, Casgevy is the first step.

1 · Reply

Coconutbeater Aug. 6 at 1:03 AM

$CRSP Aunt Cathie still believes!

1 · Reply

IBott Aug. 6 at 12:05 AM

$CRSP ARK bought 181,295 more shares today Safely Invested in Stocks

1 · Reply

puggzie1 Aug. 5 at 11:08 PM

$CRSP When is Crisper Sam stepping up to the plate to purchase some of Crisper? He needs to put his money where his mouth is instead of selling every chance he gets!

0 · Reply

Greypanz Aug. 5 at 10:35 PM

$CRSP If your an investor, time to enter is now.

1 · Reply

Rhonna_Zhonna Aug. 5 at 9:54 PM

$CRSP VRTX really sucked the life out of us though I must say, the number of patients really need to pick up, it's been like a friggin year and a half now.

0 · Reply

TheRealJayPowell Aug. 5 at 9:49 PM

$CRSP Enjoy lower lows coming for you. It is still a 4 year declining POS.

1 · Reply

legendary4090 Aug. 5 at 6:57 PM

$CRSP 52 was a good entry. might add more if it gets there again

0 · Reply

Nickmont Aug. 5 at 6:22 PM

$CRSP anyone have thoughts about gene bridging and its potential to make replace crispr before it really even starts?

1 · Reply

ZacksResearch Aug. 5 at 6:11 PM

$CRSP dips over 8% after reported Q2 loss widens! 📉 Despite an impressive 51% YTD surge, CRSP’s reported Q2 loss came in wider than last year due to a hefty $96.3M payment to Sirius Therapeutics, recorded as acquired in-process R&D expenses. Adjusted EPS was a bright spot, beating the Zacks Consensus Estimate. However, grant revenues missed significantly, weighing on the stock. Full deep dive here 👉 https://www.zacks.com/stock/news/2668686/crsp-stock-down-on-huge-q2-loss-focus-on-increasing-casgevy-adoption?cid=sm-stocktwits-2-2668686-body-6167&ADID=SYND_STOCKTWITS_TWEET_2_2668686_BODY_6167

1 · Reply

Market Cap	5.15B
Revenue (ttm)	37.31M
Net Income (ttm)	-366.25M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-981.64%
Debt to Equity Ratio	0.00

Volume	1,788,406
Avg Vol	3,450,290
Day's Range	N/A - N/A
Shares Out	86.36M
Stochastic %K	18%
Beta	1.80
Analysts	Strong Sell
Price Target	$79.96